An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.


Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 800, Dallas, TX, 75231, USA. [Email]


ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).


ABP 501,Adalimumab,Biosimilar,Efficacy,Long-term safety,Rheumatoid arthritis,

OUR Recent Articles